Emibetuzumab 化学特性,用途語,生産方法
説明
Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction,
leading to MET internalization and degradation.
臨床応用
A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and
in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.
Emibetuzumab 上流と下流の製品情報
原材料
準備製品